Literature DB >> 22375903

Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus.

Xia Li1, Lei Liu, Defang Meng, Dandan Wang, Jiyun Zhang, Dongyan Shi, Huiqing Liu, Huji Xu, Liwei Lu, Lingyun Sun.   

Abstract

Previous studies indicated that bone marrow mesenchymal stem cells (BMSCs) from patients with systemic lupus erythematosus (SLE) exhibited impaired capacities of proliferation, differentiation, secretion of cytokines, and immune modulation. In this study, we aimed to investigate whether apoptosis and senescence of SLE BMSCs were dysregulated. We found that there were increased frequencies of apoptotic and aging SLE BMSCs in comparison with those of normal controls. Notably, levels of Bcl-2 expression in SLE BMSCs were markedly decreased both at mRNA and protein levels. When BMSCs were induced to apoptosis by tumor necrosis factor-α (TNF-α) stimulation in vitro, the Bax and caspase 8 expression in SLE BMSCs was significantly increased at mRNA levels. The activity of caspase 8 was also enhanced in SLE BMSCs. More cytochrome-C-positive pellets in the cytosolic fraction of BMSCs were detected in SLE patients than in normal controls. The expression of Fas and tumor necrosis factor-α receptor 1 in SLE BMSCs was significantly upregulated compared with normal controls, and the serum levels of FasL and TNF-α were also elevated. Moreover, intracellular reactive oxygen species levels of SLE BMSCs were higher than those of normal controls, with the activation of PI3K/AKT/FoxO3 signaling pathway. Taken together, our results demonstrate increased apoptosis and senescence in SLE BMSCs, which may be associated with the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22375903     DOI: 10.1089/scd.2011.0447

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  37 in total

1.  Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties.

Authors:  Erin A Kimbrel; Nicholas A Kouris; Gregory J Yavanian; Jianlin Chu; Yu Qin; Ann Chan; Ram P Singh; Deborah McCurdy; Lynn Gordon; Ralph D Levinson; Robert Lanza
Journal:  Stem Cells Dev       Date:  2014-05-02       Impact factor: 3.272

2.  MicroRNA-663 induces immune dysregulation by inhibiting TGF-β1 production in bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus.

Authors:  Linyu Geng; Xiaojun Tang; Kangxing Zhou; Dandan Wang; Shiying Wang; Genhong Yao; Weiwei Chen; Xiang Gao; Wanjun Chen; Songtao Shi; Nan Shen; Xuebing Feng; Lingyun Sun
Journal:  Cell Mol Immunol       Date:  2018-03-26       Impact factor: 11.530

3.  Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.

Authors:  Jia-Min Zhang; Fei-Er Feng; Qian-Ming Wang; Xiao-Lu Zhu; Hai-Xia Fu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Stem Cells Transl Med       Date:  2016-07-28       Impact factor: 6.940

4.  Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling.

Authors:  Yu Tang; Hao Xie; Jinyun Chen; Linyu Geng; Haifeng Chen; Xia Li; Yayi Hou; Liwei Lu; Songtao Shi; Xiaofeng Zeng; Lingyun Sun
Journal:  Stem Cells Dev       Date:  2012-10-10       Impact factor: 3.272

Review 5.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

6.  Wnt/β-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway.

Authors:  Zhifeng Gu; Wei Tan; Guijuan Feng; Yan Meng; Biyu Shen; Hong Liu; Chun Cheng
Journal:  Mol Cell Biochem       Date:  2013-10-16       Impact factor: 3.396

Review 7.  An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis.

Authors:  Wenchao Li; Weiwei Chen; Lingyun Sun
Journal:  Kidney Dis (Basel)       Date:  2021-02-19

Review 8.  Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus.

Authors:  Wen-Yan Tang; Jia-Hua Liu; Chun-Jin Peng; Yao Liao; Jie-Si Luo; Xi Sun; Yan-Lai Tang; Xue-Qun Luo
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-03-13       Impact factor: 4.291

9.  Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study.

Authors:  Dandan Wang; Lingying Niu; Xuebing Feng; Xinran Yuan; Shengnan Zhao; Huayong Zhang; Jun Liang; Cheng Zhao; Hong Wang; Bingzhu Hua; Lingyun Sun
Journal:  Clin Exp Med       Date:  2016-06-07       Impact factor: 5.057

10.  A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.

Authors:  Dandan Wang; Xuebing Feng; Lin Lu; Joanne E Konkel; Huayong Zhang; Zhiyong Chen; Xia Li; Xiang Gao; Liwei Lu; Songtao Shi; Wanjun Chen; Lingyun Sun
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.